Updates are available Correction dated 2021-09-07
Click to view Correction: https://doi.org/10.1038/s41598-021-96648-2
-
Authors
Waghorn, Philip A.
Ferreira, Diego S.
Erstad, Derek J.
Rotile, Nicholas J.
Masia, Ricard
Jones, Chloe M.
Tu, Chuantao
Sojoodi, Mozhdeh
Chen, Yin-ching I.
Schlerman, Franklin
Wellen, Jeremy
Martinez, Robert V. P.
Tanabe, Kenneth K.
Fuchs, Bryan C.
Caravan, Peter
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK104956)
National Institute of Diabetes and Digestive and Kidney Diseases (DK104302)
National Institute of Biomedical Imaging and Bioengineering (EB009062)
NIH Office of the Director (OD025234)
- License Information
-
More Information
Article History
Received: 10 August 2020
Accepted: 28 February 2021
First Online: 17 March 2021
Change Date: 7 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-021-96648-2
Competing interests
: P.C. has equity in and is a consultant to Collagen Medical LLC, has equity in Reveal Pharmaceuticals Inc, and has research support from Pliant Therapeutics, Pfizer, Takeda, Janssen, and Indalo Therapeutics. B.C.F. has consulted for Gilead, and had research support from Collagen Medical, Enanta, and Blade Therapeutics. This work was not supported by any of these companies. F.S. and R.V.P.M. are employed by Pfizer and J. W. was employed by Pfizer at the time of the study. The other authors have declared that no conflict of interest exists.
